The Street’s Key Stock Analysts Research Reports
$ABT, $BSX, $DVA, $MDT, $SWKS, $ALL, $AZPN, $BAX, $CPK,$HRC
Investors will not receive any notable economic data for the rest of the week.
Daily HeffX-LTN reviews dozens of the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.
Below is a list of The Street’s Key analysts outlook for Key issues for Thursday as follows:
Abbott Laboratories (NYSE:ABT) was started with a Buy rating and assigned an 83 price target at UBS in a broader healthcare initiation. The consensus target price is 78.94.
Boston Scientific Corp. (NYSE:BSX) was started with a Buy rating and assigned a 45 target price at UBS. It has a 52-wk trading range of 24.54 – 39.44 and a consensus price target at 42.29.
DaVita Inc. (NYSE:DVA) analysts raised DVA to Outperform from Market Perform with a 70 price target at Raymond James.
Medtronic PLC (NYSE:MDT) was started with a Buy rating and assigned a$112 price target at UBS. The consensus target is at 104, and the 52-wk trading range is 76.41 – 100.15.
Skyworks Solutions Inc. (NASDAQ:SWKS) was raised to Equal Weight from Underweight and analysts held its target price at 76 at Morgan Stanley.
Allstate Corp. (NYSE:ALL) was maintained as Buy at Argus, but the firm lowered its target price to 106 from 115 following its Q-3 results. The 52-wk trading range is 86.77 – 105.36, and the consensus price target is at 107.40.
Aspen Technology Inc. (NASDAQ:AZPN) was raised to Buy from Hold and its price target was maintained at 100 at Canaccord Genuity. The 52-wk trading range is 65.03 – 118.86, and the consensus price target is at 105.17.
Baxter International Inc. (NYSE:BAX) was started with a Buy rating and assigned an 80 price target at UBS.
Chesapeake Utilities Corp. (NYSE:CPK) was started with a Buy rating and assigned a 100 target price at Maxim Group.
Hill-Rom Holdings Inc. (NYSE:HRC) was started with a Buy rating and assigned a 115 price target at UBS.